太阳集团tyc5997_平台(china)官方网站

FMS样酪氨酸激酶3(Flt3)多克隆抗体

Polyclonal Antibody to FMS Like Tyrosine Kinase 3 (Flt3)

CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2

  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 产品包装(模拟)
  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 产品包装(模拟)
  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 IHC图
  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 IHC图
  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 IHC图
  • PAA039Mu01.jpg Figure. Western Blot; Sample: Recombinant Flt3, Mouse.
  • FMS样酪氨酸激酶3(Flt3)多克隆抗体 Western Blot; Samples: Lane1: K562 cell lysate; Lane2: HepG2 cell lysate; Lane3: THP1 cell lysate;
    Primary Ab: 0.4µg/ml Rabbit Anti-Mouse Flt3 Antibody
    Second Ab: 0.2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对Flt3的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别Flt3。

用法

Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

赠品

相关产品

编号 适用物种:Mus musculus (Mouse,小鼠) 应用(仅供研究使用,不用于临床诊断!)
RPA039Mu01 FMS样酪氨酸激酶3(Flt3)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA039Mu01 FMS样酪氨酸激酶3(Flt3)多克隆抗体 WB; IHC; ICC; IP.
LAA039Mu71 FMS样酪氨酸激酶3(Flt3)多克隆抗体(生物素标记) WB; IHC; ICC.

参考文献

杂志 参考文献
Frontiers in physiology Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303]
PLoS One Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and … [Pubmed: 30235245]
Bioscience Reports N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858]
Molecular Neurobiology Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic … [Doi: 10.1007/s12035-017-0835-5]
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075]
留言咨询
Baidu
sogou